THE-BRAIN-FORUM
7.4.2016 11:11:51 CEST | Business Wire | Press release
The Brain Forum brings together top scientists and entrepreneurs from the world’s biggest brain initiatives. The event will run in collaboration with EPFL on 26 and 27 May at the SwissTech Convention Center in Lausanne, Switzerland.
Launched in 2013, The Brain Forum plays an important role in the progression of brain research by connecting researchers, engineers, healthcare professionals, entrepreneurs, investors, funding agencies and policy makers. In so doing, The Brain Forum helps to accelerate our understanding of the brain by translating science from bench to business, thus making laboratory innovations available to all.
Dr. Jamil El-Imad, CEO of The Brain Forum, comments: “We want to include anyone with an interest in the brain. We hope that our different but complementary experience and perspectives can help to overcome the biggest challenges of this era. You can’t build the future based on present assumptions so we need to develop our thinking and be open to spontaneous opportunities that may lead to the necessary serendipity for innovation.”
The Brain Forum has proven a great success in previous years. This year the main objectives are to enhance the attendance of the international community, to promote awareness of brain science at a global level and to stimulate worldwide, unified efforts to tackle one of the biggest healthcare challenges of this century. The event features an impressive line-up of world-renowned experts who promise to give fascinating insights into cutting-edge research, advancements in our understanding of the brain and the impact of that knowledge. International brain initiatives and regulatory bodies from the EU, USA, Japan and China will share how they are working towards improving brain research. Google will host a special session on ‘Lessons from practical machine intelligence’ followed by UBS on ‘The Workforce of the Future,’ while the popular start-up competition returns offering opportunities for start-ups to pitch to investors looking to invest in the solutions of the future.
The Brain Forum was created because scientific exploration of the brain is fundamental for tackling the challenges of the 21st century. As more and more people are affected by neurological and psychiatric conditions, there is increasing awareness of the importance of brain research to healthcare and technology. WHO recently concluded that brain disorders account for 35 per cent of the burden of all diseases in Europe and will become the major medical need of this century. In 2010, the European Brain Council published a report demonstrating that brain disorders cost Europe EUR 800 billion in 2010 – more than cardiovascular disease, cancer and diabetes combined.
Dr. El-Imad adds: “The future is both terrific and terrifying. Our aging populations are increasing the incidence and burden of many neurological and psychiatric diseases presenting huge challenges for healthcare and society, while artificial intelligence will presage a new industrial revolution, altering the workforce of the future and shifting further the balance of humans vs. machines. Technology and science will allow us to do things that we never imagined possible, but we as a society need to be prepared to deal with the consequences – good and bad – of our rapidly changing future.”
To participate - and mould the future of brain science – register at:
www.thebrainforum.org
*Source: ME NewsWire
View source version on businesswire.com: http://www.businesswire.com/news/home/20160407005582/en/
Contact:
Headline office
The Brain Forum
Christophe Tournier,
press office, +412-1517-6717
thebrainforum@farner.ch
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 14:17:00 CEST | Press release
Contributing to the International Manufacturing-X Council Showcase at Hannover Messe, to improve resilience, productivity and innovation in Manufacturing Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performanc
Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 12:32:00 CEST | Press release
Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 202620.4.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable response
PPG invests in testing line for radiation-curable coatings at Marly, France20.4.2026 11:00:00 CEST | Press release
Installation helps accelerate development cycles, reduce number of customer trials PPG (NYSE: PPG) today announced the installation of an advanced testing line for radiation-curable coatings at its R&D Center of Excellence in Marly, France. The line can test multiple curing technologies, including infrared (IR), ultraviolet (LED, excimer and arc lamps), and electron beam (EB). This investment allows the company to accurately replicate customer production conditions, helping accelerate development cycles and reduce the number of customer trials. Unlike conventional thermal curing, radiation curing requires less energy because it operates at or near ambient temperature. This reduction in energy demand can significantly lower carbon emissions by 65%*, with further gains possible when powered by renewable energy sources. In addition, UV- and EB-curable systems typically use 100% solids formulations with no solvents, reducing or eliminating volatile organic compound emissions. Beyond sustai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
